FDA has issued a Drug Safety Communication indicating that the drug tolvaptan (Samsca, Otsuka American Pharmaceuticals), used in the treatment of electrolyte disturbances, can cause irreversible liver injury with the potential to result in liver transplant or death.
On April 15, 2013, 2 pharmaceutical compounders recalled their sterile products following an alert issued by FDA.
FDA has approved aripiprazole (Abilify Maintena, Otsuka and Lundbeck) for extended-release injectable suspension for the treatment of schizophrenia.
FDA is adding its strongest warning to labels of codeine-containing products advising against their use for pain relief in children after surgery to remove tonsils or adenoids. The agency asks healthcare professionals to use alternate pain relievers instead.
WellPoint and its affiliated health plans (WellPoint) have distributed pill boxes at no extra cost to more than 187,000 at-risk members of Medicare Advantage and Prescription Drug plans across the country as a friendly reminder for them to take their medicines.
FDA has approved everolimus (Zortress, Novartis) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
Vitamin D supplementation does not slow progression of knee osteoarthritis or reduce pain associated with the condition, according to a study published recently in the Journal of the American Medical Association.
A leading epidemiologist recently suggested alternative treatments for the fungal meningitis outbreak late last year. To date, 46 deaths have been linked to contaminated steroids from compounding pharmacies.
Physicians who attended a medical school with an active gift restriction policy were subsequently less like to prescribe newly marketed psychotropic medications over older, cheaper alternatives, according to a study published in the January 2013 issue of BMJ.
FDA has approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).